Policy: MP241

Section: Medical Benefit Policy

Subject: Non-invasive Measurement of Advanced Glycation Endproducts

I. Policy: Non-invasive Measurement of Advanced Glycation Endproducts

II. Purpose/Objective:
To provide a policy of coverage regarding Non-invasive Measurement of Advanced Glycation Endproducts

III. Responsibility:
A. Medical Directors
B. Medical Management

IV. Required Definitions
1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions
Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
c. in accordance with current standards of good medical treatment practiced by the general medical community.
d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment
Medical Necessity shall mean a service or benefit that is compensable under the Medical Assistance Program and if it meets any one of the following standards:

(i) The service or benefit will, or is reasonably expected to, prevent the onset of an illness, condition or disability.
(ii) The service or benefit will, or is reasonably expected to, reduce or ameliorate the physical, mental or development effects of an illness, condition, injury or disability.
(iii) The service or benefit will assist the Member to achieve or maintain maximum functional
capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for members of the same age.

DESCRIPTION: Advanced glycation endproducts (AGE) are metabolic byproducts from non-enzymatic glycation of proteins and amino acids. They have been proposed as a biomarker for disease severity and risk prediction. Because AGEs demonstrate autofluorescence when exposed to particular wavelengths of light, spectrographic non-invasive autofluorescence readers have been developed and used to measure AGEs in the study of several diseases such as but not limited to diabetes, renal failure and cardiac disease.

EXCLUSIONS: There is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of non-invasive measurement of advanced glycation endproducts (AGES) for any indication. Therefore, the Plan does NOT provide coverage for the measurement of AGEs because it is considered to be experimental, investigational or unproven.

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in MP 15 - Experimental Investigational or Unproven Services or Treatment.

CODING ASSOCIATED WITH: Non-invasive Measurement of Advanced Glycation Endproducts

The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services.

88749 unlisted in vivo (eg, transcutaneous) laboratory service


LINE OF BUSINESS:
Eligibility and contract specific benefit limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD’s and NCD’s will supersede this policy. For PA Medicaid Business segment, this policy applies as written.

REFERENCES:


van Waateringe RP, Slagter SN, van Beek AP, et al. Skin autofluorescence, a non-invasive biomarker for advanced glycation end products, is associated with the metabolic syndrome and its individual components. Diabetol Metab Syndr. 2017;9:42

This policy will be revised as necessary and reviewed no less than annually.

Devised: 7/12/10

Reviewed: 7/11, 7/12, 7/13, 7/14, 7/15, 7/16, 6/17, 6/18